Search
Results: 1
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.
Sandra Cantilena, Luca Gasparoli, Deepali Pal, Olaf Heidenreich, Jan-Henning Klusmann, Joost HA Martens, Alexandre Faille, Alan J Warren, Mawar Karsa, Ruby Pandher, Klaartje Somers, Owen Williams, Jasper de Boer
Jul 22, 2022
BACKGROUND: Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein-driven paediatric cancer, with MLL (KMT2A)-fusions present in most cases. Direct...